Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial.

Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols / adverse effects B7-H1 Antigen Carcinoma, Transitional Cell / drug therapy Humans Platinum / therapeutic use Urinary Bladder Neoplasms / drug therapy
Atezolizumab Cancer immunotherapy Overall survival Urothelial carcinoma

Journal

European urology
ISSN: 1873-7560
Titre abrégé: Eur Urol
Pays: Switzerland
ID NLM: 7512719

Informations de publication

Date de publication:
07 2021
Historique:
received: 15 10 2020
accepted: 24 03 2021
pubmed: 28 4 2021
medline: 19 2 2022
entrez: 27 4 2021
Statut: ppublish

Résumé

Atezolizumab is an anti-PD-L1 immune checkpoint inhibitor recommended for the treatment of locally advanced or metastatic urothelial carcinoma (mUC) after prior platinum-containing chemotherapy, regardless of PD-L1 status, among other treatment settings. We conducted a long-term follow-up to the exploratory analysis of overall survival (OS) and safety for the IMvigor211 intent-to-treat (ITT) population. Patients with mUC and disease progression during or following platinum-based chemotherapy were randomised 1:1 to receive atezolizumab 1200 mg or chemotherapy (vinflunine 320 mg/m

Identifiants

DOI: 10.1016/j.eururo.2021.03.024 PMID: 33902955
pubmed: 33902955
pii: S0302-2838(21)00230-X
doi: 10.1016/j.eururo.2021.03.024
pii:
doi:

Substances chimiques

Antibodies, Monoclonal, Humanized 0
B7-H1 Antigen 0
Platinum 49DFR088MY
atezolizumab 52CMI0WC3Y

Banques de données

ClinicalTrials.gov
['NCT02302807']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7-11

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Auteurs

Michiel S van der Heijden (MS)

Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

Yohann Loriot (Y)

Gustave Roussy, Paris, France.

Ignacio Durán (I)

Hospital Universitario Virgen del Rocio, Seville, Spain.

Alain Ravaud (A)

CHU Hôpitaux de Bordeaux, Bordeaux, France.

Margitta Retz (M)

Technical University Munich, Munich, Germany.

Nicholas J Vogelzang (NJ)

Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.

Betty Nelson (B)

Genentech, Inc., South San Francisco, CA, USA.

Jingjing Wang (J)

IQVIA, Inc., Durham, NC, USA.

Xiaodong Shen (X)

Genentech, Inc., South San Francisco, CA, USA.

Thomas Powles (T)

Barts Cancer Institute, Queen Mary University of London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Carcinome transitionnel › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Produits chimiques inorganiques › Métaux › Métaux lourds › Platine › Atezolizumab Versus Chemotherapy in Patients...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Atezolizumab Versus Chemotherapy in Patients...